Singh_2024_AAPS.PharmSciTech_25_149

Reference

Title : Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Abeta(1-42) Neurotoxicity in In-Vivo Model - Singh_2024_AAPS.PharmSciTech_25_149
Author(s) : Singh A , Rakshit D , Kumar A , Mishra A , Shukla R
Ref : AAPS PharmSciTech , 25 :149 , 2024
Abstract :

Silibinin (SIL) Encapsulated Nanoliquid Crystalline (SIL-NLCs) particles were prepared to study neuroprotective effect against amyloid beta (Abeta(1-42)) neurotoxicity in Balb/c mice model. Theses NLCs were prepared through hot emulsification and probe sonication technique. The pharmacodynamics was investigatigated on Abeta(1-42) intracerebroventricular (ICV) injected Balb/c mice. The particle size, zeta potential and drug loading were optimized to be 153 +/- 2.5 nm, -21 mV, and 8.2%, respectively. Small angle X-ray (SAXS) and electron microscopy revealed to crystalline shape of SIL-NLCs. Thioflavin T (ThT) fluroscence and circular dichroism (CD) technique were employed to understand monomer inhibition effect of SIL-NLCs on Abeta(1-4). In neurobehavioral studies, SIL-NLCs exhibited enhanced mitigation of memory impairment induced on by Abeta(1-42) in T-maze and new object recognition test (NORT). Whereas biochemical and histopathological estimation of brain samples showed reduction in level of Abeta(1-42) aggregate(,) acetylcholine esterase (ACHE) and reactive oxygen species (ROS). SIL-NLCs treated animal group showed higher protection against Abeta(1-42) toxicity compared to free SIL and Donopezil (DPZ). Therefore SIL-NLCs promises great prospect in neurodegenerative diseases such as Alzheimer's disease.

PubMedSearch : Singh_2024_AAPS.PharmSciTech_25_149
PubMedID: 38954224

Related information

Inhibitor Silybin

Citations formats

Singh A, Rakshit D, Kumar A, Mishra A, Shukla R (2024)
Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Abeta(1-42) Neurotoxicity in In-Vivo Model
AAPS PharmSciTech 25 :149

Singh A, Rakshit D, Kumar A, Mishra A, Shukla R (2024)
AAPS PharmSciTech 25 :149